| Outcome . | Vancomycin–TZP (n = 114) . | Vancomycin–Cefepime (n = 114) . | P . |
|---|---|---|---|
| Actual time to AKI (median [IQR]) (days) | 7 (4–16) | >15 (NA) | .06a |
| No. (%) without resolution of AKIb | 3 (9.7) | 0 (0) | NAc |
| Length of stay (median [IQR]) (days) | 45 (16–108) | 23 (12–70) | .01a |
| Outcome . | Vancomycin–TZP (n = 114) . | Vancomycin–Cefepime (n = 114) . | P . |
|---|---|---|---|
| Actual time to AKI (median [IQR]) (days) | 7 (4–16) | >15 (NA) | .06a |
| No. (%) without resolution of AKIb | 3 (9.7) | 0 (0) | NAc |
| Length of stay (median [IQR]) (days) | 45 (16–108) | 23 (12–70) | .01a |
Abbreviations: AKI, acute kidney injury; IQR, interquartile range; NA, not applicable; TZP, piperacillin-tazobactam.
aLog-rank test stratified according to matched pairs.
bData available for 40 patients, 31 in the TZP–vancomycin group and 9 in the cefepime–vancomycin group.
cNo estimation possible; resolution of AKI did not vary within groups.
| Outcome . | Vancomycin–TZP (n = 114) . | Vancomycin–Cefepime (n = 114) . | P . |
|---|---|---|---|
| Actual time to AKI (median [IQR]) (days) | 7 (4–16) | >15 (NA) | .06a |
| No. (%) without resolution of AKIb | 3 (9.7) | 0 (0) | NAc |
| Length of stay (median [IQR]) (days) | 45 (16–108) | 23 (12–70) | .01a |
| Outcome . | Vancomycin–TZP (n = 114) . | Vancomycin–Cefepime (n = 114) . | P . |
|---|---|---|---|
| Actual time to AKI (median [IQR]) (days) | 7 (4–16) | >15 (NA) | .06a |
| No. (%) without resolution of AKIb | 3 (9.7) | 0 (0) | NAc |
| Length of stay (median [IQR]) (days) | 45 (16–108) | 23 (12–70) | .01a |
Abbreviations: AKI, acute kidney injury; IQR, interquartile range; NA, not applicable; TZP, piperacillin-tazobactam.
aLog-rank test stratified according to matched pairs.
bData available for 40 patients, 31 in the TZP–vancomycin group and 9 in the cefepime–vancomycin group.
cNo estimation possible; resolution of AKI did not vary within groups.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
